Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraineJames M. Martinez, Sandra Garcês, Michael E. Hodsdon et al.|Cephalalgia|2020Cited by 14
[P1–044]: SAFETY OF SOLANEZUMAB IN PHASE 3 STUDIES IN INDIVIDUALS WITH MILD ALZHEIMER's DISEASE DEMENTIAChristopher Carlson, Eric Siemers, Greg Anglin et al.|Alzheimer s & Dementia|2017Cited by 1